← All trials
NCT06895486
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 29, 2025
- Primary completion
- Nov 13, 2026
- Completion date
- Nov 13, 2026
- First posted
- Mar 26, 2025
- Last posted
- Apr 1, 2025
- Enrollment
- 675
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PATHLead sponsor
- PT Bio FarmaCollaborator
- Bill and Melinda Gates FoundationCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
- CevaxinOfficial
- Technical Resources International, Inc. (TRI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.